{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-035377","form_type":"8-K","ticker":"BIXT","cik":"0001445815","company_name":"BIOXYTRAN, INC","filed_at":"2022-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.692316+00:00","generated_at":"2026-06-21T04:41:35.308750+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Bioxytran registers Indian subsidiary, Pharmalectin India, to commercialize ProLectin-M pending CDSCO approval","bullets":["Wholly owned subsidiary Pharmalectin India Private Limited registered on Sept 7, 2022 in India.","Subsidiary to sponsor clinical trials and commercialize Bioxytran's products if CDSCO approval is obtained.","Indian manufacturing plant is FDA-approved; no distributor identified yet.","Press release and updated corporate presentation issued Dec 14, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-035377","json":"https://secwatch.observer/filing/0001493152-22-035377.json","markdown":"https://secwatch.observer/filing/0001493152-22-035377.md","text":"https://secwatch.observer/filing/0001493152-22-035377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445815/000149315222035377/0001493152-22-035377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445815/000149315222035377/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T04:41:35.308750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}